Tony Coles, Yumanity Executive Chairman (Yumanity)
June 24, 2020 08:05 AM EDTUpdated 10:05 AM
Deals
R&D
Discovery

Burned by Alzheimer’s fail­ures, a cau­tious Mer­ck turns to a start­up biotech for some pre­clin­i­cal neu­ro pro­grams

John Carroll

Editor & Founder

Af­ter play­ing a lead­ing role in prov­ing that the BACE the­o­ry was worth­less in treat­ing Alzheimer’s, Mer­ck is go­ing back to the draw­ing board …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times